🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementThrew up at work today - do I tell my boss why? — need advice

Threw up at work today - do I tell my boss why? — need advice

tony_orlando Wed, Sep 11, 2024 at 2:24 PM 49 replies 2,859 viewsPage 1 of 10
This thread is more than 21 months old. Information may be outdated. Consider searching for more recent discussions.
tony_orlando
Member
234
1,123
Nov 2024
Orlando, FL
Sep 11, 2024 at 2:24 PM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

What would genuinely help is knowing whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

I have searched first, so if this is covered somewhere point me at it and I will read it.

8 3NauseaFreeNow, SteveThurs, B12Beth and 5 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Sep 11, 2024 at 2:51 PM#2

Taking the question as asked, rather than the general version of it. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

7 2dave_SLC, FDA_TrackerJim, ricardo_MIA and 4 others
Reply Quote Save Share Report
SkepticalSean
Member
98
345
Jan 2025
Maine
Sep 11, 2024 at 3:18 PM#3
PeptideChemSF said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

That is correct as far as it goes, and here is where it stops going. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

Last edited: Sep 11, 2024 at 7:18 PM
6 1emma_london, tammy_FL, Dr.LipidDallas and 3 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Sep 11, 2024 at 3:45 PM#4
tony_orlando said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Can confirm the pattern tony_orlando describes. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

5 0lori_vegas, Dr.PulmRoch, maya_sedona and 2 others
Reply Quote Save Share Report
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Sep 11, 2024 at 6:12 PM#5

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

4 24LipidDoc_ATL, BariatricNurseD, MASHdoc_SA and 1 other
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register